Boothbay Fund Management, LLC Prothena Corp Public LTD CO Transaction History

Boothbay Fund Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$21.63 - $57.65 $1.04 Million - $2.78 Million	-48,162 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$11.0 - $28.24 $847,957 - $2.18 Million	-77,087 Reduced 61.55%	48,162 $1.21 Million
Q4 2020 Feb 12, 2021	BUY	$10.12 - $13.94 $1.27 Million - $1.75 Million	125,249 New	125,249 $1.5 Million
Q2 2019 Aug 14, 2019	SELL	$8.85 - $12.49 $177,000 - $249,800	-20,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$10.32 - $14.49 $206,400 - $289,800	20,000 New	20,000 $243,000

182

42.7M

77.7K

92.7K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $1.02B
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.